RMD
RESMED INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 2 to Feb 9 ▼ 3 days of insider sells: $2.1M by 4 insiders, avg $266.02
- Mar 2 to Mar 9 ▼ 3 days of insider sells: $2.0M by 3 insiders, avg $253.74
- Apr 1 to Apr 7 ▼ 2 days of insider sells: $1.8M by 3 insiders, avg $225.23
- Aug 5 to Aug 7 ▼ 2 days of insider sells: $2.8M by 2 insiders, avg $217.58
- Sep 2 to Sep 8 ▼ 2 days of insider sells: $1.3M by 2 insiders, avg $224.44
- Sep 11 ▲ Ro Khanna bought $1,001 - $15,000, last disclosed Oct 9
- Oct 7 ▼ 1 insider sell $1.1M at $226.33
- Oct 23 ▼ 1 insider sell $102.0K at $255.00
- Oct 29 ▲ ResMed reported Q1 FY2027 results with revenue of $1.415B (up 6% rep…
- Oct 29 ▲ Earnings: RMD Q1 2027 Earnings: EPS $2.91 (+7.8% vs est)
- Nov 2 ▼ Canaccord Genuity downgrades
- Nov 9 ▼ 1 insider sell $1.2M at $235.35
Signal stack
Where each data set points today.
- InsidersBEARISH
4 insiders sold $15.6M.
- InstitutionsMIXED
Q2 2026: 55 added (1 new), 50 trimmed or exited. Largest new: Sih Partners, Lllp $21.2M.
- AnalystsBULLISH
14 of 27 rate it Buy or better. Median target $270.00 (+13%).
- Short sellersSTEADY
Short interest −12.2% to 10.47M shares. 7.0 days to cover, ≈7.4% of shares.
- TrendUPTREND
3% above its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| FIRST TRUST ADVISORS LP | ADD | $444.1M |
| MORGAN STANLEY | TRIM | $375.9M |
| NORDEA INVESTMENT MANAGEMENT AB | ADD | $269.6M |
| UBS Group AG | ADD | $251.3M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $220.2M |
| CITIGROUP INC | ADD | $150.9M |
| NORGES BANK | TRIM | $129.5M |
| Amundi | TRIM | $117.8M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
27 analystsPrice is inside the target range. Median implies +13%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 2, 2026 | Canaccord Genuity DOWNGRADE | Hold |
| Oct 30, 2026 | Citigroup MAINTAIN | Neutral |
| Oct 30, 2026 | RBC Capital MAINTAIN | Outperform |
| Oct 30, 2026 | Wells Fargo MAINTAIN | Equal-Weight |
| Oct 30, 2026 | Keybanc MAINTAIN | Overweight |
| Sep 15, 2026 | RBC Capital UPGRADE | Outperform |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
FARRELL PETER C Director Nov 11, 2026 | TAX W/H | $39.6K |
Bloomer Aaron Chief Financial Officer Nov 11, 2026 | TAX W/H | $256.4K |
Farrell Michael J. Chairman and CEO Nov 11, 2026 | TAX W/H | $811.4K |
Farrell Michael J. Chairman and CEO Nov 11, 2026 | TAX W/H | $517.3K |
Farrell Michael J. Chairman and CEO Nov 11, 2026 | TAX W/H | $570.3K |
Rider Michael J Global General Counsel Nov 11, 2026 | TAX W/H | $128.2K |
Rider Michael J Global General Counsel Nov 11, 2026 | TAX W/H | $116.7K |
Rider Michael J Global General Counsel Nov 11, 2026 | TAX W/H | $169.6K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
17 filings · 2 press releases · 3 bullish · 3 bearish · 11 neutral- NEUTRAL 144Nov 9, 2026
Michael J. Farrell, an officer and director of ResMed, filed a Form 144 notice of intent to sell…
The sale is small relative to market cap and follows a pattern of monthly option-exercise-and-sell transactions by this insider. No material signal for the stock; monitor for any change in the…
- BULLISH 8-KOct 29, 2026
ResMed reported Q1 FY2027 results with revenue of $1.415B (up 6% reported, 7% core constant…
The maintained FY2027 guidance despite a strong Q1 beat suggests management is comfortable with the current trajectory, but the lack of an upward revision may temper near-term enthusiasm. Watch for…
- BULLISH PRESS-RELEASEOct 29, 2026
Resmed reported Q1 FY2027 revenue of $1.415B (up 6% YoY, 7% core constant currency) and non-GAAP…
The maintained FY2027 guidance suggests management sees current momentum as sustainable. Watch for any future guidance revision given the strong Q1 beat and the impact of the MatrixCare divestiture…
- BEARISH INST-CLUSTEROct 16, 2026
An institutional cluster for ResMed (RMD) shows a bearish net conviction in Q3 2026, with 3…
The selling is broad-based across three asset managers, while the sole buyer is a single active manager. Monitor upcoming earnings for any guidance revision or competitive pressure commentary that…
All RMD filing & press-release reports (19)
- 144 reportNov 9, 2026
- 8-K reportOct 29, 2026
- PRESS-RELEASE reportOct 29, 2026
- INST-CLUSTER reportOct 16, 2026
- 144 reportOct 7, 2026
- DEFA14A reportOct 1, 2026
- DEF 14A reportOct 1, 2026
- PRESS-RELEASE reportOct 1, 2026
- CLUSTER reportSep 10, 2026
- CLUSTER reportAug 11, 2026
- PRESS-RELEASE reportJul 7, 2026
- PRESS-RELEASE reportJun 1, 2026
- PRESS-RELEASE reportMay 19, 2026
- CLUSTER reportApr 1, 2026
- CLUSTER reportApr 1, 2026
- PRESS-RELEASE reportApr 1, 2026
- CLUSTER reportMar 2, 2026
- CLUSTER reportMar 2, 2026
- INST-CLUSTER reportFeb 28, 2026